TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injectionTH103 was ...

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX ...

Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...

Clinicians from Fox Chase Cancer Center at Temple University Health share their highlights from the Society of Urologic ...

The combination of denifanstat and resmetirom was generally well-tolerated over the duration of the study, with no safety signals. No Serious Adverse Events (SAEs) occurred, and there were no ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...